OBJECTIVES: We investigated sex-based differences in eligibility for and outcomes after receipt of advanced heart failure (HF) therapies. BACKGROUND: Although women are more likely to die from HF than men, registry data suggest that women are less likely to receive heart transplant (HT) or left ventricular assist device (LVAD) for largely unknown reasons. METHODS: We performed a single-center retrospective cohort study of patients evaluated for advanced HF therapies from 2012 to 2016. Logistic regression was used to determine the association of sex with eligibility for HT/LVAD. Competing risks and Kaplan-Meier analysis were used to examine survival. RESULTS: Of 569 patients (31% women) evaluated, 223 (39.2%) were listed for HT and 81 (14.2%) received destination (DT) LVAD. Women were less likely to be listed for HT (adjusted odds ratio [OR] 0.36, 95% confidence interval [CI] 0.21-0.61; P < .0001), based on allosensitization (P < .0001) and obesity (P = .02). Women were more likely to receive DT LVAD (adjusted OR 2.29, 95% CI 1.23-4.29; P = .01). Survival was similar between men and women regardless of whether they received HT and DT LVAD or were ineligible for therapy. CONCLUSION: Women are less likely to be HT candidates, but more likely to receive DT LVAD.
OBJECTIVES: We investigated sex-based differences in eligibility for and outcomes after receipt of advanced heart failure (HF) therapies. BACKGROUND: Although women are more likely to die from HF than men, registry data suggest that women are less likely to receive heart transplant (HT) or left ventricular assist device (LVAD) for largely unknown reasons. METHODS: We performed a single-center retrospective cohort study of patients evaluated for advanced HF therapies from 2012 to 2016. Logistic regression was used to determine the association of sex with eligibility for HT/LVAD. Competing risks and Kaplan-Meier analysis were used to examine survival. RESULTS: Of 569 patients (31% women) evaluated, 223 (39.2%) were listed for HT and 81 (14.2%) received destination (DT) LVAD. Women were less likely to be listed for HT (adjusted odds ratio [OR] 0.36, 95% confidence interval [CI] 0.21-0.61; P < .0001), based on allosensitization (P < .0001) and obesity (P = .02). Women were more likely to receive DT LVAD (adjusted OR 2.29, 95% CI 1.23-4.29; P = .01). Survival was similar between men and women regardless of whether they received HT and DT LVAD or were ineligible for therapy. CONCLUSION:Women are less likely to be HT candidates, but more likely to receive DT LVAD.
Authors: James K Kirklin; David C Naftel; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2014-04-21 Impact factor: 10.247
Authors: Leslee J Shaw; Carl J Pepine; Joe Xie; Puja K Mehta; Alanna A Morris; Neal W Dickert; Keith C Ferdinand; Martha Gulati; Harmony Reynolds; Sharonne N Hayes; Dipti Itchhaporia; Jennifer H Mieres; Elizabeth Ofili; Nanette K Wenger; C Noel Bairey Merz Journal: J Am Coll Cardiol Date: 2017-07-18 Impact factor: 24.094
Authors: Lars H Lund; Kiran K Khush; Wida S Cherikh; Samuel Goldfarb; Anna Y Kucheryavaya; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Daniel C Chambers; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2017-07-20 Impact factor: 10.247
Authors: Alanna A Morris; Robert T Cole; S Raja Laskar; Andreas Kalogeropoulos; J David Vega; Andrew Smith; Javed Butler Journal: J Card Fail Date: 2015-03-24 Impact factor: 5.712
Authors: Christina Magnussen; Alexander M Bernhardt; Francisco M Ojeda; Florian M Wagner; Jan Gummert; Theo M M H de By; Thomas Krabatsch; Paul Mohacsi; Meike Rybczynski; Dorit Knappe; Bjoern Sill; Tobias Deuse; Stefan Blankenberg; Renate B Schnabel; Hermann Reichenspurner Journal: J Heart Lung Transplant Date: 2017-07-04 Impact factor: 10.247
Authors: James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: Nazir Savji; Wouter C Meijers; Traci M Bartz; Vijeta Bhambhani; Mary Cushman; Matthew Nayor; Jorge R Kizer; Amy Sarma; Michael J Blaha; Ron T Gansevoort; Julius M Gardin; Hans L Hillege; Fei Ji; Willem J Kop; Emily S Lau; Douglas S Lee; Ruslan Sadreyev; Wiek H van Gilst; Thomas J Wang; Markella V Zanni; Ramachandran S Vasan; Norrina B Allen; Bruce M Psaty; Pim van der Harst; Daniel Levy; Martin Larson; Sanjiv J Shah; Rudolf A de Boer; John S Gottdiener; Jennifer E Ho Journal: JACC Heart Fail Date: 2018-07-11 Impact factor: 12.035
Authors: Lucy J Boothroyd; Laurie J Lambert; Georgeta Sas; Jason R Guertin; Anique Ducharme; Éric Charbonneau; Michel Carrier; Renzo Cecere; Jean E Morin; Peter Bogaty Journal: Can J Cardiol Date: 2013-08-23 Impact factor: 5.223
Authors: Avishay Grupper; Emilija M Nestorovic; Richard C Daly; Natasa M Milic; Lyle D Joyce; John M Stulak; David L Joyce; Brooks S Edwards; Naveen L Pereira; Sudhir S Kushwaha Journal: Transplant Direct Date: 2016-09-13
Authors: Rebecca S Steinberg; Aditi Nayak; Michael A Burke; Morgan Aldridge; S Raja Laskar; Kunal Bhatt; Lakshmi Sridharan; Mahmoud Abdou; Tamer Attia; Andrew Smith; Mani Daneshmand; J David Vega; Divya Gupta; Alanna A Morris Journal: Clin Transplant Date: 2021-10-26 Impact factor: 2.863
Authors: Christine Park; Mandisa-Maia Jones; Samantha Kaplan; Felicitas L Koller; Julius M Wilder; L Ebony Boulware; Lisa M McElroy Journal: Int J Equity Health Date: 2022-02-12
Authors: Imo A Ebong; Ersilia M DeFilippis; Eman A Hamad; Eileen M Hsich; Varinder K Randhawa; Filio Billia; Mahwash Kassi; Anju Bhardwaj; Mirnela Byku; Mrudala R Munagala; Roopa A Rao; Amy E Hackmann; Claudia G Gidea; Teresa DeMarco; Shelley A Hall Journal: Front Cardiovasc Med Date: 2022-07-11